ACE2-Mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function

Huijing Xia, Sonia Suda, Sharell Bindom, Yumei Feng, Susan Gurley, Dale Seth, L. Gabriel Navar, Eric Lazartigues

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Oxidative stress in the central nervous system mediates the increase in sympathetic tone that precedes the development of hypertension. We hypothesized that by transforming Angiotensin-II (AngII) into Ang-(1-7), ACE2 might reduce AngII-mediated oxidative stress in the brain and prevent autonomic dysfunction. To test this hypothesis, a relationship between ACE2 and oxidative stress was first confirmed in a mouse neuroblastoma cell line (Neuro2A cells) treated with AngII and infected with Ad-hACE2. ACE2 overexpression resulted in a reduction of reactive oxygen species (ROS) formation. In vivo, ACE2 knockout (ACE2 -/y) mice and non-transgenic (NT) littermates were infused with AngII (10 days) and infected with Ad-hACE2 in the paraventricular nucleus (PVN). Baseline blood pressure (BP), AngII and brain ROS levels were not different between young mice (12 weeks). However, cardiac sympathetic tone, brain NADPH oxidase and SOD activities were significantly increased in ACE2 -/y. Post infusion, plasma and brain AngII levels were also significantly higher in ACE2 -/y, although BP was similarly increased in both genotypes. ROS formation in the PVN and RVLM was significantly higher in ACE2 -/y mice following AngII infusion. Similar phenotypes, i.e. increased oxidative stress, exacerbated dysautonomia and hypertension, were also observed on baseline in mature ACE2 -/y mice (48 weeks). ACE2 gene therapy to the PVN reduced AngII-mediated increase in NADPH oxidase activity and normalized cardiac dysautonomia in ACE2 -/y mice. Altogether, these data indicate that ACE2 gene deletion promotes age-dependent oxidative stress, autonomic dysfunction and hypertension, while PVN-targeted ACE2 gene therapy decreases ROS formation via NADPH oxidase inhibition and improves autonomic function. Accordingly, ACE2 could represent a new target for the treatment of hypertension-associated dysautonomia and oxidative stress.

Original languageEnglish (US)
Article numbere22682
JournalPloS one
Volume6
Issue number7
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Oxidative stress
angiotensin II
Neurology
Angiotensin II
central nervous system
Oxidative Stress
oxidative stress
Central Nervous System
Paraventricular Hypothalamic Nucleus
dysautonomia
Primary Dysautonomias
hypertension
NADPH Oxidase
reactive oxygen species
Reactive Oxygen Species
Brain
mice
Hypertension
brain
Gene therapy

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

ACE2-Mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. / Xia, Huijing; Suda, Sonia; Bindom, Sharell; Feng, Yumei; Gurley, Susan; Seth, Dale; Navar, L. Gabriel; Lazartigues, Eric.

In: PloS one, Vol. 6, No. 7, e22682, 01.08.2011.

Research output: Contribution to journalArticle

Xia, Huijing ; Suda, Sonia ; Bindom, Sharell ; Feng, Yumei ; Gurley, Susan ; Seth, Dale ; Navar, L. Gabriel ; Lazartigues, Eric. / ACE2-Mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. In: PloS one. 2011 ; Vol. 6, No. 7.
@article{4dd9f5f15dfe415aaa729f143dea7a47,
title = "ACE2-Mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function",
abstract = "Oxidative stress in the central nervous system mediates the increase in sympathetic tone that precedes the development of hypertension. We hypothesized that by transforming Angiotensin-II (AngII) into Ang-(1-7), ACE2 might reduce AngII-mediated oxidative stress in the brain and prevent autonomic dysfunction. To test this hypothesis, a relationship between ACE2 and oxidative stress was first confirmed in a mouse neuroblastoma cell line (Neuro2A cells) treated with AngII and infected with Ad-hACE2. ACE2 overexpression resulted in a reduction of reactive oxygen species (ROS) formation. In vivo, ACE2 knockout (ACE2 -/y) mice and non-transgenic (NT) littermates were infused with AngII (10 days) and infected with Ad-hACE2 in the paraventricular nucleus (PVN). Baseline blood pressure (BP), AngII and brain ROS levels were not different between young mice (12 weeks). However, cardiac sympathetic tone, brain NADPH oxidase and SOD activities were significantly increased in ACE2 -/y. Post infusion, plasma and brain AngII levels were also significantly higher in ACE2 -/y, although BP was similarly increased in both genotypes. ROS formation in the PVN and RVLM was significantly higher in ACE2 -/y mice following AngII infusion. Similar phenotypes, i.e. increased oxidative stress, exacerbated dysautonomia and hypertension, were also observed on baseline in mature ACE2 -/y mice (48 weeks). ACE2 gene therapy to the PVN reduced AngII-mediated increase in NADPH oxidase activity and normalized cardiac dysautonomia in ACE2 -/y mice. Altogether, these data indicate that ACE2 gene deletion promotes age-dependent oxidative stress, autonomic dysfunction and hypertension, while PVN-targeted ACE2 gene therapy decreases ROS formation via NADPH oxidase inhibition and improves autonomic function. Accordingly, ACE2 could represent a new target for the treatment of hypertension-associated dysautonomia and oxidative stress.",
author = "Huijing Xia and Sonia Suda and Sharell Bindom and Yumei Feng and Susan Gurley and Dale Seth and Navar, {L. Gabriel} and Eric Lazartigues",
year = "2011",
month = "8",
day = "1",
doi = "10.1371/journal.pone.0022682",
language = "English (US)",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - ACE2-Mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function

AU - Xia, Huijing

AU - Suda, Sonia

AU - Bindom, Sharell

AU - Feng, Yumei

AU - Gurley, Susan

AU - Seth, Dale

AU - Navar, L. Gabriel

AU - Lazartigues, Eric

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Oxidative stress in the central nervous system mediates the increase in sympathetic tone that precedes the development of hypertension. We hypothesized that by transforming Angiotensin-II (AngII) into Ang-(1-7), ACE2 might reduce AngII-mediated oxidative stress in the brain and prevent autonomic dysfunction. To test this hypothesis, a relationship between ACE2 and oxidative stress was first confirmed in a mouse neuroblastoma cell line (Neuro2A cells) treated with AngII and infected with Ad-hACE2. ACE2 overexpression resulted in a reduction of reactive oxygen species (ROS) formation. In vivo, ACE2 knockout (ACE2 -/y) mice and non-transgenic (NT) littermates were infused with AngII (10 days) and infected with Ad-hACE2 in the paraventricular nucleus (PVN). Baseline blood pressure (BP), AngII and brain ROS levels were not different between young mice (12 weeks). However, cardiac sympathetic tone, brain NADPH oxidase and SOD activities were significantly increased in ACE2 -/y. Post infusion, plasma and brain AngII levels were also significantly higher in ACE2 -/y, although BP was similarly increased in both genotypes. ROS formation in the PVN and RVLM was significantly higher in ACE2 -/y mice following AngII infusion. Similar phenotypes, i.e. increased oxidative stress, exacerbated dysautonomia and hypertension, were also observed on baseline in mature ACE2 -/y mice (48 weeks). ACE2 gene therapy to the PVN reduced AngII-mediated increase in NADPH oxidase activity and normalized cardiac dysautonomia in ACE2 -/y mice. Altogether, these data indicate that ACE2 gene deletion promotes age-dependent oxidative stress, autonomic dysfunction and hypertension, while PVN-targeted ACE2 gene therapy decreases ROS formation via NADPH oxidase inhibition and improves autonomic function. Accordingly, ACE2 could represent a new target for the treatment of hypertension-associated dysautonomia and oxidative stress.

AB - Oxidative stress in the central nervous system mediates the increase in sympathetic tone that precedes the development of hypertension. We hypothesized that by transforming Angiotensin-II (AngII) into Ang-(1-7), ACE2 might reduce AngII-mediated oxidative stress in the brain and prevent autonomic dysfunction. To test this hypothesis, a relationship between ACE2 and oxidative stress was first confirmed in a mouse neuroblastoma cell line (Neuro2A cells) treated with AngII and infected with Ad-hACE2. ACE2 overexpression resulted in a reduction of reactive oxygen species (ROS) formation. In vivo, ACE2 knockout (ACE2 -/y) mice and non-transgenic (NT) littermates were infused with AngII (10 days) and infected with Ad-hACE2 in the paraventricular nucleus (PVN). Baseline blood pressure (BP), AngII and brain ROS levels were not different between young mice (12 weeks). However, cardiac sympathetic tone, brain NADPH oxidase and SOD activities were significantly increased in ACE2 -/y. Post infusion, plasma and brain AngII levels were also significantly higher in ACE2 -/y, although BP was similarly increased in both genotypes. ROS formation in the PVN and RVLM was significantly higher in ACE2 -/y mice following AngII infusion. Similar phenotypes, i.e. increased oxidative stress, exacerbated dysautonomia and hypertension, were also observed on baseline in mature ACE2 -/y mice (48 weeks). ACE2 gene therapy to the PVN reduced AngII-mediated increase in NADPH oxidase activity and normalized cardiac dysautonomia in ACE2 -/y mice. Altogether, these data indicate that ACE2 gene deletion promotes age-dependent oxidative stress, autonomic dysfunction and hypertension, while PVN-targeted ACE2 gene therapy decreases ROS formation via NADPH oxidase inhibition and improves autonomic function. Accordingly, ACE2 could represent a new target for the treatment of hypertension-associated dysautonomia and oxidative stress.

UR - http://www.scopus.com/inward/record.url?scp=79960810124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960810124&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0022682

DO - 10.1371/journal.pone.0022682

M3 - Article

C2 - 21818366

AN - SCOPUS:79960810124

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e22682

ER -